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ABSTRACT
Objective: To examine the differences over time in health-care costs asso-
ciated with incident adverse events in children and adolescents treated
with antipsychotic agents compared to an untreated control sample.
Method: A retrospective cohort design evaluating South Carolina’s Med-
icaid medical and pharmacy claims between January 1996 and December
2005 was employed for 4140 children and adolescents prescribed antip-
sychotic medications, and a random sample of 4500 children not treated
with psychotropic medications. The main outcome measures were total
health-care costs and emergency, inpatient, and outpatient services use.
Results: Patients with the focal adverse medical conditions incurred sig-
niﬁcantly higher total care costs (34% higher, on average, over 8–9 years)
compared with those without these conditions (F = 710.08; P < 0.0001) or
to children not treated with psychotropic medications (F = 2855.54;
P < 0.0001). Patients with incident adverse events associated with antip-
sychotic treatment had signiﬁcantly higher rates/time under Medicaid
coverage of outpatient, emergency, and inpatient services utilization than
the control sample patients, controlling for preexisting conditions, receipt
of multiple psychotropic medications, and individual risk factor differ-
ences for males, adolescents, and non-African Americans.
Conclusions: The development of adverse medical conditions related to
antipsychotic medication use in children and adolescents is signiﬁcantly
associated with higher total costs of health care and to utilization of
outpatient, emergency, and inpatient services over time.
Keywords: adolescents, antipsychotic medications, children, health-care
costs, health-care utilization.
Introduction
During the past two decades, efforts to characterize deﬁciencies in
the public mental health systems nationwide in meeting the needs
of seriously emotionally disturbed children have been intensiﬁed
[1,2]. Moreover, there has been increased recognition of the
changing patterns of utilization and expenditures away from
inpatient and toward outpatient care, with an emphasis on child-
serving sectors, such as emergency departments, schools, and
pediatric clinics [3–6]. In addition, the importance of Medicaid in
funding a broadening range of services in the 0 to 17 age group has
been documented [7,8]. To our knowledge, only one published
study has examined the factors associated with the use of mental
health, general health, and school-based services among school-
aged children with psychopathology [9]. Zahner and Daskalakis
reported that sociodemographics (e.g., age, sex, and race) were
signiﬁcantly correlated with service use in all three sectors of
mental health, general health, and school-based services, as were
the child’s illness proﬁle (i.e., Child Behavior Checklist score,
parent ratings of child impairment, and general health problems)
[9].
During the same time interval, a substantial increase in the use
of antipsychotic drugs, notably second-generation antipsychotics
(SGAs), in pediatric patients treated in privately and publicly
insured systems [10–13], and in both primary and specialty care
settings [14], has been documented. Extant clinical trial studies
and case reports indicate that the use of conventional antipsychot-
ics and SGAs in children is associated with higher rates of adverse
events, such as: extrapyramidal symptoms, seizures, somnolence/
sedation, weight gain/obesity, Type II diabetes mellitus, increased
prolactin levels and the ensuing sexual/reproductive adverse
events, and cerebrovascular or cardiovascular events (e.g.,
arrhythmias, ischemic events, orthostasis, and exacerbation of
hypertension) [15,16]. Increasingly, SGAs are prescribed in com-
bination with other psychotropic agents for treatment of various
comorbid conditions (e.g., attention deﬁcit hyperactivity disorder
and bipolar disorder), or behavioral or psychotic disorders with
aggressive features (e.g., comorbid conduct or oppositional
deﬁant disorders), which introduces the possibility for cumulative
adverse events [17–19] and increased medication costs.
Finally, the prevalence of obesity and its associated compli-
cations (e.g., diabetes mellitus, primary hypertension) in the
general pediatric population have also increased signiﬁcantly
during the past two decades [20,21]. The age-adjusted rates of
medical disorders in the adult and child populations indicate that
over 20% of children have two or more risk factors for cardio-
vascular disease (obesity, metabolic, and hypertension) [22,23],
and that antipsychotics and coprescribed antidepressants and
mood-stabilizing agents may further increase the risk of these
adverse events [19]. A growing database indicates that cardi-
ometabolic disorders may differentially affect African Americans
of all ages [24,25].
The increased prevalence of cardiometabolic disorders in
this age group may be partially mediated by the use of antipsy-
chotic and other psychotropic agents that disrupt the metabolic
milieu or neurological/cardiovascular function [19,26,27]. This
increased rate of diabetes mellitus and associated dyslipidemia in
pediatric populations portends a greater risk for cardiovascular
disease, which is the most frequent cause of premature death
in individuals with mood and psychotic disorders [28–32].
Although the use of these medications is associated with
decreased pediatric acute care and increased outpatient service
utilization [6], the impact of developing adverse events/medical
conditions associated with treatment with antipsychotic or other
psychotropic medications on children’s health-care utilization
patterns and costs has heretofore not been investigated.
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The aim of this analysis is to explore how the development of
adverse events/medical conditions subsequent to antipsychotic
treatment impacts health-care costs and service utilization over
time compared with patients not treated with any psychotropic
medication. The development of incident adverse conditions
associated with antipsychotic treatment was hypothesized to be
an important predictor of the total cost of health-care and of
service utilization (amount and type) over time for pediatric
clients, controlling for other factors in the cost equation, such
as preexisting or noniatrogenic medical conditions, the need
for multiple pharmacotherapy interventions for multiple/
complicated disorders, and individual risk factors (i.e., race, sex,
or age).
Methods
Cohort Selection
Claims data for the South Carolina Medicaid program were
obtained through the state’s Ofﬁce of Research and Statistics.
Data from both medical and pharmacy claims were used, with
encrypted client demographics and identiﬁers to protect client
conﬁdentiality. Each Medicaid medical claim identiﬁes a service
encounter, and gives the date of service, the International Clas-
siﬁcation of Diseases (ICD) Ninth Revision Clinical Modiﬁca-
tion, diagnosis codes, and the cost to Medicaid (claims
payment) related to that visit (Visit ﬁle). Pharmacy claims iden-
tiﬁed the medication dispensed, the date the prescription was
ﬁlled, and the cost of the medication to Medicaid (Pharmacy
ﬁle). A separate data ﬁle regarding eligibility was used to sum-
marize the demographics for each client (Person ﬁle). The data-
bases are frequently updated before being made available for
analysis. This study was approved by the University of South
Carolina Institutional Review Board as exempt from human
subject research guidelines under 45 Code of Federal Regula-
tions Part 46.
Medical and pharmacy claims for the calendar years January
1, 1996 through December 31, 2005 were used to identify a
cohort of child and adolescent clients (ages 17 and under) eligible
for Medicaid for 12 months in each calendar year included in this
analysis, who had a service encounter, and who were newly
prescribed one of ﬁve atypical antipsychotics (i.e., aripiprazole,
ziprasidone, quetiapine, risperidone, olanzapine), or haloperidol,
a conventional antipsychotic, between January 1, 1998 and
December 31, 2003. The date of ﬁrst prescription of an antipsy-
chotic medication was deﬁned as the selection encounter date for
the treated cohort.
Adverse Event Coding
Medical conditions that were detected in the 24 months before
each client’s selection encounter date were coded as “pre-
existing” for this study. If the client developed a medical condi-
tion subsequent to the prescription of the antipsychotic
medication, new variables were created for these “incident”
events. There was no overlap between “preexisting” and “inci-
dent” conditions. Any of these medical conditions detected in the
control sample were coded for the comparison analysis, either at
the time they developed or in total over time. Based on extant
results from clinical trials and case reports, the preexisting and
incident medical conditions of interest were categorized as:
obesity and excessive weight gain (ICD-9 codes: 278, 278.00,
278.01, 783.1, 783.2), dyslipidemia (ICD-9 codes: 272, 288.0,
285.9), Type II diabetes mellitus, (ICD-9 codes: 250, 250.00–
251.92 with 5th digit = 0,2), hypertension (ICD-9 codes: 401–
405), cardiovascular events (ICD-9 codes: myocardial infarction
410–412, ischemic/pulmonary heart disease 413–416, 428–429,
arrhythmias 426–427, and cardiomyopathy 425), cerebrovascu-
lar events (ICD-9 codes: cerebrovascular disease 436–437,
cerebrovascular accident 435, cerebrovascular hemorrhage 430–
434, and peripheral vascular disease 440–448), orthostatic
hypotension/syncope (ICD-9 codes: 458, 780.2), involuntary
movements/extrapyramidal symptoms, including tardive or oro-
facial dyskinesia (ICD-9 codes: 333 to 333.99, 781.0), seizures/
convulsions (ICD-9 codes: 780.3, 780.39), sedation/somnolence
(ICD-9 codes: 780.09, 780.54), amenorrhea (ICD-9 code:
626.0), oligomenorrhea (ICD-9 code: 626.1), erectile dysfunc-
tion (ICD-9 code: 302.72, 607.84), pituitary disorders, including
hyperprolactinemia (ICD-9 code: 253.xx), irregular menses
(ICD-9 code: 626.4), gynecomastia (ICD-9 code: 611.1, 611.6),
or galactorrhea (ICD-9 code: 676). All of these conditions have
been found to be increasingly prevalent in child and adolescent
populations or have been consistently identiﬁed as adverse effects
of antipsychotic and coprescribed psychotropic medications
[15–19].
The number of medical condition diagnoses has been widely
used as a measure of comorbidity [33], and correlates with
severity of disability and mortality [34]. For this investigation,
the number of medical diagnoses for preexisting conditions or
incident adverse events was summed separately, and the total
number for each was then dichotomized to represent “had one or
more focal medical conditions” for each 6-month interval of
their Medicaid coverage for the total cost regression and “had
one or more preexisting or adverse events” for the total years
each patient was in the Medicaid database for the service utili-
zation analyses. Previous studies indicate that some of these
conditions develop quickly, e.g., neurological and some cardio-
vascular conditions, while others, e.g., metabolic and endocrine
conditions, may develop over 1 to 3 years, and subsequently lead
to the development of additional cardiovascular conditions
[17–19,26,27]. Therefore, because the time periods examined
were either in 6-month intervals or total time in the Medicaid
data set, we feel that dichotomous coding of the preexisting and
incident medical conditions adequately represents each indepen-
dent variable in the regressions performed.
Furthermore, the number of psychotropic medications pre-
scribed across classes of agents (i.e., antipsychotics, antidepres-
sants, mood stabilizers, and psychostimulants) that each client
was prescribed while receiving services in this data set was
summed, and then dichotomized as “multiple psychotropic medi-
cations” if the total medications totaled two or more. For those
clients treated with multiple antipsychotic medications, sequen-
tial use (i.e., switching from one antipsychotic to another within
a 30-day period) versus concomitant use of over 30 days was
determined by ﬂagging the start date and end date of each medi-
cation and determining how many days the prescriptions of the
medications overlapped. Brief treatment of 1 to 5 months with an
antipsychotic was differentiated from long-term treatment of 6 to
90+ months.
A common approach to investigating the effect of a clinical
practice or policy on a health-care system is to model its effect on
the average cost per service user over time. In line with this
approach, the total cost of all of a client’s outpatient visits,
emergency department visits, inpatient days, and pharmacy
claims was calculated for each 6-month interval of their Medic-
aid coverage following the client’s start date on antipsychotic
medications and for the 24 months before this start date (period
used to establish preexisting conditions) to represent the main
dependent variable, total cost of care. In the control group, the
client’s start date was his/her entry into the Medicaid data set.
Because the Medicaid reimbursement rate changed only once and
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at different times for some of the services during the study period,
and we are primarily interested in the relative, not absolute,
change in totals costs over time, the calculated total costs per
6-month period were not adjusted for inﬂation using the medical
care components of the Consumer Price Index. Total utilization
of any outpatient medical services (ofﬁce-based, laboratory,
hospital-based diagnostic, etc.), emergency department visits,
and inpatient days over time were also calculated as dependent
measures to determine the signiﬁcant subgroup service utilization
patterns or reasons for differences in total care costs, i.e., whether
the preexisting or incident medical conditions or polypharmacy
use (multiple psychotropic medications prescribed) led to differ-
ential use of outpatient or acute services.
Data Analyses
Data for the total cost variable were analyzed using the PROC
MIXED facility in SAS version 9.1 (SAS Institute Inc., Cary, NC)
for repeated measures designs. Given the longitudinal nature of
the design, the inherent correlation of repeated assessments, and
the potential for missing data across measurement occasions,
random effects regression was deemed most appropriate for these
analyses because it accommodates both randomly missing obser-
vations and subjects measured at different time points and esti-
mates random subject-speciﬁc effects. Because the Studentized
residuals using the raw total cost variable were skewed, but those
using the log of this variable were normally distributed, a log
transformation of the total cost was used as the dependent
variable.
One random effects regression analysis was performed to
examine two interaction effects: control versus treated group by
time, and medical conditions versus no medical conditions group
by time. Covariates were modeled as either time varying (i.e.,
preexisting/incident/any medical condition; multiple psychotro-
pic medication use) or time invariant (e.g., age, sex, race, control
or treatment group). Dependent variable estimates were com-
puted via a restricted likelihood method. All multiple comparison
analyses employed the Tukey–Kramer adjustment to protect the
overall 0.05 signiﬁcance level. The estimated log predicted means
by occasion and treatment group or adverse events group were
then retransformed to their natural scale using Duan’s smearing
technique [35]. Plots for the retransformed log predicted mean
estimates by occasion and treatment group or medical conditions
groups are presented, controlling for the individual risk or mul-
tiple psychotropic medications covariates.
Because the dependent variables of outpatient, emergency,
and inpatient service utilization involve counts of events that
were not normally distributed, a negative binomial regression
model (PROC GENMOD facility in SAS version 9.1; SAS Insti-
tute Inc.) was employed, which calculated a ratio of the log rate
of service utilization to the log total time (years) each client was
covered in the Medicaid data set. These three regression analy-
ses were performed with three independent variables: total
number of adverse events or medical conditions incident to
antipsychotic treatment, total number of preexisting medical
conditions in the treated cohort or those not related to psycho-
tropic medications in the control sample, and the prescription of
multiple (2+) psychotropic medications, which was used as a
measure of severity of the psychiatric condition, dichotomously
coded [33,34]. Individual risk factors, i.e., race (African
American/non-African American), sex (male/female), and age
(12 and under/13 and over) were used as control variables
because service utilization has been shown to differ according to
these demographics [9].
Results
The treated cohort consisted of 3635 children and adolescents:
68.2% were male, 41% African American, 42% Caucasian
(Table 1). The mean age of the treated cohort was 10.4
(SD = 3.6) years at the time of antipsychotic initiation. The
random sample control group was more predominantly female
and African American, with a slightly lower mean age of 7.3
years (SD = 3.5). Although clients in the treated cohort were
about 3 years older at selection into the cohort (start date of the
antipsychotic medication) than those in the control sample, data
were compiled on the treated cohort for 2 years before their
selection date for analysis of the preexisting conditions, making
their average age at start date in this data set more comparable to
the control group (8.4 years). The antipsychotic medications
were used to treat Axis I disorders of: schizophrenia, major
affective disorders, other psychotic disorders, attention deﬁcit/
hyperactivity disorder, and conduct/oppositional deﬁant disor-
der. Sixty-ﬁve percent of the children were treated with an
antipsychotic long-term (6 to 90 months), and 69% was treated
with two or more psychotropic medications.
Furthermore, the control group was in the Medicaid data set
for an average of 9.0 years compared with the treated group
being in it, on average, 8.3 years. Therefore, combining the
treated cohort and control sample provide comparable and
adequate time periods for examining differences in types of con-
ditions developing over time in a low-income population and
their costs of care. Not all of the 6575 clients in the combined
treated and control group continued treatment for the 10 years
covered in this analysis: after 4 years in the data set, N = 5760
remained; after 8 years in the data set, N = 2783 remained.
Nevertheless, this N of cases is adequate to establish the relative
comparison and trend lines needed for this analysis.
The incidence rates for developing the disparate adverse
events after taking any SGA or conventional antipsychotic
Table 1 Descriptive analysis of the treated cohort and control sample
Indicator
Treated
cohort
N (%)
Control
sample
N (%)
Sex
Male 2825 (68.2) 2528 (56.2)
Female 1315 (31.8) 1972 (43.8)
Race
Caucasian 1722 (42.0) 842 (18.7)
African American 1680 (41.0) 3405 (75.7)
Hispanic 13 (0.2) 42 (1.0)
Asian 6 (0.1) 9 (0.2)
Unknown, mixed 715 (17.3) 195 (4.3)
Psychiatric diagnoses
Schizophrenia 358 (8.7)
Major affective disorders 2261 (54.6)
Other psychotic disorders 1149 (27.8)
Conduct disorder or oppositional
deﬁant disorder
2970 (71.7)
Attention deﬁcit hyperactivity disorder 3258 (78.7)
Comorbid disorders
Epilepsy 954 (23.0) 31 (0.7)
Central nervous system disorders 919 (22.2) 228 (5.1)
Organic brain syndrome or severe
mental retardation
704 (17.0) 164 (3.6)
Congenital heart defects 146 (3.5) 108 (2.4)
Substance-related disorder 490 (11.8) 116 (2.6)
Concomitant psychotropic medications
Tricyclic antidepressants 716 (17.3)
Selective serotonin reuptake inhibitors 2367 (57.2)
Psychostimulants 3170 (76.6)
Mood stabilizers 1898 (45.9)
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medications are presented in Table 2, along with the preexisting
(before antipsychotic agent exposure) prevalence rates. Forty-
nine percent of the combined treated and control group “had one
or more preexisting medical conditions,” and 62.5% “developed
one or more of these medical conditions after antipsychotic treat-
ment” at some time period during the study. Table 3 presents the
summary means and SDs for the four main dependent variables
employed in these analyses.
Total Cost of Care
Figure 1 presents the regression results for the retransformed
predicted log total health-care costs/time per patient for the
control group, the treated group without medical conditions, and
the treated group with medical conditions. Estimated log total
costs comparisons indicated a signiﬁcant treatment group
(treated/control) by time interaction and a signiﬁcant medical
conditions group (medical conditions/no medical conditions) by
time interaction (Table 4). As imaged in Figure 1, the control
group’s average total cost varied little over the 9 years of service
modeled, averaging $900 to $1200 per 6-month interval, using
the retransformed estimated means [35]. Average total cost for
clients treated with antipsychotic medications without medical
conditions varied greatly in the 2 years before initiation of antip-
sychotic treatment, from an average of $8411 to $3156 per time
interval, but then declined steadily after antipsychotic treatment
was initiated, from an average of $9590 to $1676 per time
interval. Average total costs for clients treated with antipsychotic
medications with incident adverse medical conditions also varied
substantially before the start of antipsychotic treatment, from an
average of $19,665 to $4,965 per time interval, and were about
85% higher than those for clients without preexisting medical
conditions. After the start of antipsychotic treatment, these
average costs decreased over time, ranging from $12,536 to
$2,487 per time interval, and were about 22% higher than those
for clients without adverse medical conditions. Across the 8 to
9 years under study, the treated group with incident medical
conditions incurred total care costs that were 34% higher than
those for the treated groups without these medical conditions.
Outpatient Services
Results of the negative binomial regression predicting the log
ratio of the rate of total outpatient service utilization/time in this
Medicaid data set (Table 5) indicate that pediatric clients treated
with antipsychotic medications had a signiﬁcantly higher rate/
time of outpatient services utilization during their time in the
Medicaid data set than the control sample clients, as do those
who developed incident adverse events, controlling for signiﬁcant
differences for males, non-African Americans, and those with
preexisting medical conditions.
Emergency Services
As shown in Table 5, pediatric clients treated with antipsychotic
medications had a signiﬁcantly lower rate of emergency service
utilization during their coverage period under Medicaid, but
those who developed incident adverse events had signiﬁcantly
higher rates/time of emergency service utilization, controlling for
signiﬁcant differences in rates of emergency service use for ado-
lescents, non-African Americans, and those with preexisting
medical conditions.
Inpatient Days
Results of the negative binomial regression predicting the log
ratio of rate of total inpatient service utilization/time in the
Medicaid data set (Table 5) indicate that pediatric patients
treated with antipsychotic medications did not differ in their
ratio of rate of inpatient service utilization/time from the control
sample clients, but those who developed incident adverse events
had signiﬁcantly higher rates of inpatient utilization/time, con-
trolling for individual risk factor differences among males, ado-
Table 2 Prevalence and incidence rates for adverse events/conditions in 4500 random sample of pediatric Medicaid population and 4140 cohort of youth
prescribed antipsychotic medications
Adverse effect or condition
Random sample
prevalence rate, N (%)
Cohort prevalence before AP
treatment rate, N (%)
Cohort incidence after AP
treatment rate, N (%)
Obesity, weight gain 388 (8.6) 240 (5.8) 542 (13.9)
Type 2 diabetes mellitus 85 (1.9) 86 (2.1) 125 (3.1)
Dyslipidemia 486 (10.8) 51 (1.2) 124 (3.0)
Cerebrovascular disorder 64 (1.4) 46 (1.1) 54 (1.3)
Cardiovascular disorder 151 (3.4) 237 (5.7) 330 (8.5)
Hypertension 171 (3.8) 27 (0.7) 76 (1.8)
Involuntary movements/EPS 55 (1.2) 147 (3.6) 187 (4.5)
Sedation/somnolence 306 (6.8) 329 (7.9) 676 (17.7)
Convulsions, seizures 173 (3.8) 593 (14.3) 361 (10.2)
Sexual/reproductive conditions 296 (6.6) 117 (2.8) 343 (8.5)
AP, antipsychotic; EPS, extrapyramidal symptoms.
Table 3 Unadjusted descriptive statistics on the combined
antipsychotic-treated cohort and control sample across all time periods
(N = 6575)
Variable Mean SD Minimum Maximum
Outpatient service 326.29 435.01 0 5,765
Emergency service 5.88 7.60 0 180
Inpatient days 8.12 22.03 0 345
Total cost 4,155.96 9,971.06 0.50 452,784.27
Table 4 Mixed model regression results for log total costs of care by
interactions, individual risk factors, medical conditions, and multiple medi-
cations (likelihood ratio test: df = 209; c2 = 50,550.67; P 0.0001)
Independent variables df F-value P
Time ¥ control sample 1 47.10 <0.0001
Time ¥medical conditions 1 10.92 <0.0001
Male 1 8.03 0.005
Adolescent, 13–17 1 44.68 <0.0001
African American 1 49.79 <0.0001
Prescribed multiple medications 1 1887.71 <0.0001
Antipsychotics and Pediatric Care Costs 719
lescents, non-African Americans, and those with preexisting
medical conditions or prescribed multiple psychotropic
medications.
Discussion
Our overarching hypothesis that the development of adverse
medical conditions associated with antipsychotic treatment has
become a signiﬁcant factor in predicting total cost of service and
pharmacy utilization over time was supported, controlling for
individual risk factors, preexisting conditions, and need for mul-
tiple psychotropic medications (severity/complexity of the psy-
chiatric illness). Pediatric patients who have preexisting medical
conditions or develop adverse medical conditions associated with
their antipsychotic treatment exhibit signiﬁcantly higher total
health-care costs, by about 34% over time. These results harmo-
nize with limited extant ﬁndings regarding the signiﬁcant inﬂu-
ence of comorbid medical conditions/health problems on general
Figure 1 Retransformed estimated log total costs over time by control sample, treated cohort without medical conditions, and treated cohort with medical
conditions.
Table 5 Negative binomial regressions predicting log ratio of rate of outpatient, emergency, and inpatient service utilization to time in Medicaid
(N = 6575) (goodness-of-ﬁt: deviance/df = 1.14; 1.11; 0.81, respectively)
Source
Outpatient services
estimate (SE)
Emergency services
estimate (SE)
Inpatient services
estimate (SE)
Intercept 3.44 (0.05)** -1.15 (0.06)** -1.64 (0.15)**
Control sample -0.75 (0.05)** 0.44 (0.06)** -0.08 (0.13)
Incident adverse events 0.25 (0.03)** 0.22 (0.03)** 0.62 (0.09)**
Male 0.11 (0.02)** -0.02 (0.03) 0.15 (0.07)*
African American -0.32 (0.02)** -0.15 (0.03)** -0.26 (0.06)**
Aged 13 to 17 -0.06 (0.03) 0.14 (0.03)** 0.74 (0.08)**
Preexisting medical conditions 0.41 (0.03)** 0.73 (0.04)** 1.11 (0.07)**
Prescribed multiple medications 0.08 (0.04) 0.09 (0.04)* 0.47 (0.11)**
*signiﬁcant at P = 0.05; **signiﬁcant at P < 0.0001.
SE, standard error of the mean.
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health and mental health care, controlling for sociodemographic
differences (e.g., age, sex, and race) [9]. Clients with comorbid
medical problems, either preexisting or iatrogenic, have been
found to remain in the service system for longer periods of
time [9] and to use more medical services [36]. Comorbid
medical condition severity/complexity, operationalized in this
study as preexisting conditions in the treated cohort and
nonpharmacologically-induced medical conditions in the control
sample, has also been shown to have a major inﬂuence on
average annual cost of care among severely mentally ill adults
[36].
Our results extend these earlier ﬁndings regarding the rela-
tionship between comorbid medical conditions and health-care
utilization costs to the development of incident adverse events/
medical conditions associated with antipsychotic treatment.
Among privately insured youth, reductions in inpatient and out-
patient mental health service intensity and costs were noted from
1997 until 2000, but were accompanied by increases in costs
related to psychotropic medications [6]. These results demon-
strate that service utilization and cost trends in the general
health-care system by pediatric clients also need to be examined
relative to the increase in adverse events associated with
increased use of antipsychotic or psychotropic medications for a
more complete understanding of the overall impact of these
changes in the use of psychiatric medications.
There are several methodological issues that limit the infer-
ences and interpretations that can be drawn from this analysis.
For example: 1) the cohort was retrospectively ascertained, using
secondary, observational techniques; 2) structured research and
clinical interviews were not employed to conﬁrm any of the
diagnosed medical disorders; 3) the recording of adverse events
and preexisting medical conditions was based on spontaneous
patient reporting to the treating physician and upon the ICD-9
codes being properly submitted to Medicaid and are, conse-
quently, likely to be underestimates; 4) these data report associa-
tions, and, as a result, directions of causality cannot be inferred;
and 5) there is no way to estimate how representative this Med-
icaid cohort is in relation to those in other states and service
systems, and the results may not be generalizable to non-
Medicaid covered cohorts.
Alternatively, the perspective provided by the longitudinal
database has important strengths: 1) the cohort represents a
large, heterogeneous group of children and adolescents pre-
scribed antipsychotics for varying periods of exposure, ranging
from brief- (1–5 months) to long-term (i.e., 6–90+ months) treat-
ment in addition to a control group; 2) previous studies have
found that although Medicaid databases provide less detailed
information on the individuals than a structured research inter-
view, the physician diagnoses and utilization data are more
reliable than client or family self-reports [37,38]; and 3) the
utilization and cost outcomes related to antipsychotic and other
psychotropic medication use are clinically relevant and of sub-
stantial health-care management importance.
The patterns of psychiatric service utilization and expendi-
tures have changed rapidly over the past 15 years, shifting away
from inpatient and toward outpatient care [3–6], and have been
accompanied by a substantial increase in the use of antipsychotic
drugs in pediatric patients [10–14]. These medications have been
shown to be quite efﬁcacious in controlling psychotic and aggres-
sive features in children and adolescents. Nevertheless, in the
pediatric clients examined herein, the development of adverse
medical conditions associated with antipsychotic treatment sig-
niﬁcantly impacted all aspects of their health-care utilization and
costs. They received more signiﬁcantly outpatient, more
emergency, and more inpatient services than those without the
incident adverse medical conditions, controlling for other
explanatory factors. Both psychiatric and primary care providers
need to increase their familiarity with the adverse events associ-
ated with the use of antipsychotics and other psychotropic agents
in young populations and strive to minimize these tolerability
and safety issues. Finally, the impact of adverse events on care
costs needs to enter cost-modeling initiatives that aim to inform
cost-effective approaches to the selection and sequencing
of antipsychotic and other psychotropic therapy in pediatric
populations.
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